

August 14, 2025

Summary of Consolidated Financial Results for the Nine Months Ended June 30, 2025 (Based on Japanese GAAP)

Company name: MedPeer, Inc.
 Stock exchange listing: Tokyo
 Stock code: 6095 URL <https://medpeer.co.jp/>
 Representative: Chief Executive Officer Naoki Goto
 Contacts: Chief Financial Officer Toshio Hirabayashi TEL 03-4405-4905
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: Yes
 Holding of financial results meeting: No

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended June 30, 2025 (from October 1, 2024 to June 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	9,068	(20.8)	744	(27.6)	700	(31.9)	436	1.7
June 30, 2024	11,445	7.1	1,028	24.7	1,029	20.5	429	5.0

Note: Comprehensive income For the nine months ended June 30, 2025: ¥435 million [(2.8)%]
 For the nine months ended June 30, 2024: ¥448 million [8.5%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
June 30, 2025	20.09	-
June 30, 2024	19.77	-

Note: Quarterly net income per share after adjusting for potential shares is not included because there is no dilution effect, although there are potential shares.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2025	14,658	9,800	66.8
September 30, 2024	15,554	9,451	60.7

Reference: Equity
 As of June 30, 2025: ¥9,791 million
 As of September 30, 2024: ¥9,442 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended September 30, 2024	-	0.00	-	4.50	4.50
Fiscal year ending September 30, 2025	-	0.00	-	-	-
Fiscal year ending September 30, 2025 (Forecast)				0.00	0.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Forecast of consolidated financial results for the fiscal year ending September 30, 2025 (from October 1, 2024 to September 30, 2025)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending September 30, 2025	12,400	(17.0)	770	(40.4)	820	(35.1)	500	(66.3)	23.02

Note: Revisions to the earnings forecasts most recently announced: None

* **Notes**

- (1) Significant changes in the scope of consolidation during the period: Yes

Excluded: 2 companies (Mediplat Inc., Fitsplus Inc.)

- (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

- (3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

- (4) Number of issued shares (common shares)

- (i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	22,010,330 shares
As of September 30, 2024	21,986,410 shares

- (ii) Number of treasury shares at the end of the period

As of June 30, 2025	281,258 shares
As of September 30, 2024	266,383 shares

- (iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Nine months ended December 31, 2024	21,720,758 shares
Nine months ended June 30, 2024	21,705,495 shares

- * Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm:nothing

- * Proper use of earnings forecasts, and other special matters

Forward-looking statements, such as earnings forecasts, contained in this material are based on information available to the Company at the time of the event and certain assumptions that the Company deems reasonable, and are not intended to be a promise by the Company to realize them. In addition, actual results may differ from forecasts due to various factors. For the process on which earnings forecasts are based and precautions for using earnings forecasts, please refer to "1. Qualitative Information on Financial Results for the this quarter (3) Explanation of Forward-Looking Information such as Consolidated Earnings Forecasts."

Quarterly consolidated balance sheet

(Thousands of yen)

	As of September 30, 2024	As of June 30, 2025
Assets		
Current assets		
Cash and deposits	7,280,009	7,260,651
Notes and accounts receivable - trade, and contract assets	2,648,055	2,254,381
Work in process	19,751	27,364
Other	417,640	301,698
Allowance for doubtful accounts	(6,729)	(1,669)
Total current assets	10,358,728	9,842,426
Non-current assets		
Property, plant and equipment		
Buildings, net	290,123	284,102
Tools, furniture and fixtures, net	91,554	92,365
Other, net	1,165	-
Total property, plant and equipment	382,843	376,468
Intangible assets		
Goodwill	1,830,126	1,650,208
Software	104,217	119,141
Customer-related assets	2,013,922	1,882,778
Total intangible assets	3,948,266	3,652,127
Investments and other assets		
Shares of subsidiaries and associates	244,687	292,320
Investment securities	128,122	36,357
Leasehold deposits	241,834	245,295
Deferred tax assets	230,615	199,105
Other	19,640	13,930
Total investments and other assets	864,900	787,009
Total non-current assets	5,196,010	4,815,605
Total assets	15,554,738	14,658,031

	As of September 30, 2024	As of June 30, 2025
Liabilities		
Current liabilities		
Accounts payable - trade	75,301	206,117
Accounts payable - other	340,374	292,194
Short-term borrowings	10,000	10,000
Current portion of long-term borrowings	524,976	524,976
Accrued consumption taxes	205,497	52,010
Income taxes payable	756,318	118,422
Provision for bonuses	171,042	90,339
Provision for bonuses for directors (and other officers)	4,762	1,790
Provision for point card certificates	147,888	144,093
Contract liabilities	42,621	113,263
Other	284,895	227,419
Total current liabilities	2,563,680	1,780,627
Non-current liabilities		
Long-term borrowings	2,625,072	2,231,340
Asset retirement obligations	122,730	124,080
Deferred tax liabilities	727,374	651,252
Retirement benefit liability	64,531	70,635
Total non-current liabilities	3,539,708	3,077,308
Total liabilities	6,103,388	4,857,936
Net assets		
Shareholders' equity		
Share capital	2,256,559	2,261,965
Capital surplus	2,255,805	2,261,211
Retained earnings	5,238,820	5,577,469
Treasury shares	(300,783)	(300,783)
Total shareholders' equity	9,450,400	9,799,862
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(10,951)	(11,097)
Remeasurements of defined benefit plans	3,122	2,354
Total accumulated other comprehensive income	(7,828)	(8,743)
Share acquisition rights	8,778	8,976
Total net assets	9,451,350	9,800,095
Total liabilities and net assets	15,554,738	14,658,031

Quarterly consolidated statement of income

(Thousands of yen)

	Nine months ended June 30, 2024	Nine months ended June 30, 2025
Net sales	11,445,921	9,068,652
Cost of sales	6,206,834	4,836,327
Gross profit	5,239,087	4,232,324
Selling, general and administrative expenses	4,210,259	3,487,884
Operating profit	1,028,827	744,440
Non-operating income		
Interest income	74	3,424
Share of profit of entities accounted for using equity method	39,905	47,632
Insurance claim income	5,003	-
Other	1,902	12,275
Total non-operating income	46,885	63,332
Non-operating expenses		
Interest expenses	10,219	17,121
Loss on retirement of non-current assets	10,621	1,408
Compensation expenses	21,384	7,650
TOB expense	-	73,953
Other	4,451	6,840
Total non-operating expenses	46,675	106,973
Ordinary profit	1,029,037	700,799
Extraordinary losses		
Impairment losses	281,519	-
Total extraordinary losses	281,519	-
Profit before income taxes	747,518	700,799
Income taxes - current	406,817	308,652
Income taxes - deferred	(106,218)	(44,243)
Total income taxes	300,599	264,409
Profit	446,918	436,389
Profit attributable to non-controlling interests	17,821	-
Profit attributable to owners of parent	429,097	436,389

Quarterly consolidated statement of comprehensive income

(Thousands of yen)

	Nine months ended June 30, 2024	Nine months ended June 30, 2025
Profit	446,918	436,389
Other comprehensive income		
Valuation difference on available-for-sale securities	1,780	(146)
Remeasurements of defined benefit plans, net of tax	(635)	(767)
Total other comprehensive income	1,144	(914)
Comprehensive income	448,063	435,475
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	430,241	435,475
Comprehensive income attributable to non-controlling interests	17,821	-

(Notes on segment information, etc.)

Segment Information

The nine months of the previous fiscal year (October 1, 2023 to June 30, 2024)

1. Information on sales and the amount of profit or loss for each reported segment, as well as information on the breakdown of revenues

(Unit: 1 thousand yen)

	Reportable segments				Other (Note) 3	Adjustment amount (Note) 1	Interim Consolidated Statements of Income (Note)2
	Doctor Platform	Marketing Support	Medical Institution Support Platform	Total			
Sales							
Goods or services to be transferred at one time	1,233,079	701,346	183,132	2,117,559	830,497	-	2,948,056
Goods or services that are transferred over a period of time	1,670,897	5,730,873	194,266	7,596,037	901,827	-	8,497,865
Revenue generated from customer contracts	2,903,977	6,432,220	377,399	9,713,596	1,732,325	-	11,445,921
Other Earnings	-	-	-	-	-	-	-
Revenues from external customers	2,903,977	6,432,220	377,399	9,713,596	1,732,325	-	11,445,921
Transactions with other segments	14,880	19,476	-	34,356	661	(35,018)	-
Total	2,918,857	6,451,696	377,399	9,747,953	1,732,986	(35,018)	11,445,921
Segment Profit or Loss	1,374,347	622,150	(144,407)	1,852,090	220,553	(1,043,816)	1,028,827

Note: 1 Adjustments for segment profit or loss include 21,865 thousand yen for inter-segment transaction elimination and 1,065,682 thousand yen for company-wide expenses not allocated to each reporting segment.

2 Segment profit or loss is adjusted for operating income in the quarterly consolidated statements of income.

3 The "Other" category is a business segment that is not included in the reporting segments, and includes preventive medicine platform business, health tech-related event business, new business, etc.

The nine months of the current fiscal year (October 1, 2024 to June 30, 2025)

1. Information on sales and the amount of profit or loss for each reported segment, as well as information on the breakdown of revenues

(Unit: 1 thousand yen)

	Reportable segments				Other (Note) 3	Adjustment amount (Note) 1	Interim Consolidated Statements of Income (Note)2
	Doctor Platform	Marketing Support	Medical Institution Support Platform	Total			
Sales							
Goods or services to be transferred at one time	1,234,128	654,721	-	1,888,850	74,911	-	1,963,761
Goods or services that are transferred over a period of time	1,530,922	5,259,181	260,526	7,050,630	54,260	-	7,104,891
Revenue generated from customer contracts	2,765,051	5,913,903	260,526	8,939,481	129,171	-	9,068,652
Other Earnings	-	-	-	-	-	-	-
Revenues from external customers	2,765,051	5,913,903	260,526	8,939,481	129,171	-	9,068,652
Transactions with other segments	2,300	80,610	-	82,910	-	(82,910)	-
Total	2,767,351	5,994,513	260,526	9,022,391	129,171	(82,910)	9,068,652
Segment Profit or Loss	1,256,094	455,230	(30,981)	1,680,342	(14,412)	(921,489)	744,440

Note: 1 Adjustments for segment profit or loss include 5,005 thousand yen for inter-segment transaction elimination and 926,495 thousand yen for company-wide expenses that have not been allocated to each reporting segment.

2 Segment profit or loss is adjusted for operating income in the quarterly consolidated statements of income.

3 The "Other" category is a business segment that is not included in the reporting segments, and includes preventive medicine platform business, health tech-related event business, new business, etc.

2. Changes to Reporting Segments, etc.

From the interim consolidated accounting period under review, the Group's reporting segments will be divided into the following segments: the Doctor Platform Business, which provides digital marketing support services for pharmaceutical companies and medical device manufacturers using the physician-only community site MedPeer, and the Doctor Platform Business, which provides contract MR/MSL services for pharmaceutical companies and content production services for pharmaceutical companies and medical device manufacturers. We have decided to change the segment to three segments: "Marketing Support Business" and "Medical Institution Support Platform Business" to support the operational efficiency of medical institutions and medical sites.

Segment information for the previous interim consolidated accounting period is disclosed based on the classification of reporting segments for the current interim consolidated accounting period.